Medipharm Labs Corp's stock has shown a modest uptick this week, reflecting investor sentiment amid recent developments in the cannabis sector.
Medipharm Labs Corp (LABS.TO) has experienced a price increase of 6.67% this week, closing at C$0.08. This positive movement comes after recent company announcements and broader industry trends that may impact its growth trajectory.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$27.77M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.85
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 53.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+53.8% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
58.7%
Annualized
90-Day Vol
68.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.06 | C$0.05 – C$0.07 |
| 60 trading days | C$0.06 | C$0.04 – C$0.08 |
| 90 trading days | C$0.05 | C$0.04 – C$0.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Medipharm Labs has reported positive financial results recently, investors should remain cautious due to the company's historical performance metrics and the volatility typical in the cannabis sector.
Medipharm Labs Corp's Market Cap Stands at C$34.2 Million
The company's market capitalization reflects its current valuation, which could see shifts depending on upcoming financial disclosures and market conditions.
Bull case
The recent positive Q2 2026 results, which include a net income and a second consecutive quarter of positive adjusted EBITDA, suggest that Medipharm Labs is on a path to recovery and growth. The company has the potential to serve the expanding U.S. pharmaceutical market, which could further boost its prospects.
Bear case
Despite the recent gains, Medipharm Labs still operates at a loss, with a profit margin of -12.0% and a negative return on equity. Investors should weigh these factors alongside the inherent risks of investing in the cannabis industry.
Price Action Overview
Medipharm Labs Corp's stock closed at C$0.08, reflecting no change in price for the day but a notable increase of 6.67% over the past week. Year-to-date, the stock has gained 14.29%, indicating a positive trend amidst the fluctuating cannabis market.
Advertisement
Recent Company Developments
Recent headlines indicate that Medipharm Labs has reported positive financial results for Q2 2026, including a net income and an adjusted EBITDA of $0.9 million. This marks the company's strongest quarterly performance since 2019 and highlights its potential for recovery. Additionally, the company is well-positioned to serve the growing U.S. pharmaceutical and clinical research market following the rescheduling of certain cannabis products.
Technical Picture
From a technical perspective, Medipharm Labs is currently trading above its 50-day moving average of C$0.07, which is a positive sign, reflecting a 7.2% increase from the current price. The 200-day moving average also stands at C$0.07, indicating a longer-term positive trend. The stock has a 52-week range of C$0.06 to C$0.10, placing it at about 50% of its range. With a beta of 0.93, the stock exhibits lower volatility compared to the market average.
Insider Activity
No recent insider trading activity has been reported for Medipharm Labs Corp, which may indicate a period of stability among the company's leadership.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
